Limits...
Evaluation of hydrophobic nanoparticulate delivery system for insulin.

Singnurkar PS, Gidwani SK - Indian J Pharm Sci (2008)

Bottom Line: Insulin encapsulation efficiency was 95.7±1.2%.Insulin hydrophobic nanoparticles suppressed insulin release promoted sustained release in pH 7.4 phosphate buffer and shown to protect insulin from enzymatic degradation in vitro in presence of chymotripsin.Nanoencapsulated insulin was bioactive, demonstrated through both in vivo and in vitro.

View Article: PubMed Central - PubMed

Affiliation: USV Limited, B. S. D. Marg, Govandi, Mumbai-400 088, India.

ABSTRACT
Insulin loaded hydrophobic nanoparticles were prepared by solvent diffusion followed by lyophilization. Nanoparticles were characterized for mean size by dynamic laser scattering and for shape by scanning electron microscopy. Insulin encapsulation efficiency, in vitro stability of nanoparticles in presence of proteolytic enzymes and in vitro release were determined by high pressure liquid chromatography analysis. The biological activity insulin from the nanopraticles was estimated by enzyme-linked immunosorbant assay and in vivo using Wister diabetic rats. Nanoparticles ranged 0.526±0.071 μm in diameter. Insulin encapsulation efficiency was 95.7±1.2%. Insulin hydrophobic nanoparticles suppressed insulin release promoted sustained release in pH 7.4 phosphate buffer and shown to protect insulin from enzymatic degradation in vitro in presence of chymotripsin. Nanoencapsulated insulin was bioactive, demonstrated through both in vivo and in vitro.

No MeSH data available.


In vitro release behavior of insulin hydrophobic nanoparticles. ♦ Percent cumulative human insulin release with time from insulin nanoparticles in pH 7.4 phosphate buffer (n=3)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3040864&req=5

Figure 0002: In vitro release behavior of insulin hydrophobic nanoparticles. ♦ Percent cumulative human insulin release with time from insulin nanoparticles in pH 7.4 phosphate buffer (n=3)

Mentions: Human insulin release profile from the nanoparticles was shown in fig. 2. Each is generally characterized by slow release rate, no bust effect was observed. The possible explanation for the slow release rate in the pH 7.4 phosphate buffer USP could be due to deposition of hydrophobic coat over insulin-zinc-HP-β-CD. Degradation of insulin observed over the extended time intervals indicating the instability of human insulin to the experimental conditions.


Evaluation of hydrophobic nanoparticulate delivery system for insulin.

Singnurkar PS, Gidwani SK - Indian J Pharm Sci (2008)

In vitro release behavior of insulin hydrophobic nanoparticles. ♦ Percent cumulative human insulin release with time from insulin nanoparticles in pH 7.4 phosphate buffer (n=3)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3040864&req=5

Figure 0002: In vitro release behavior of insulin hydrophobic nanoparticles. ♦ Percent cumulative human insulin release with time from insulin nanoparticles in pH 7.4 phosphate buffer (n=3)
Mentions: Human insulin release profile from the nanoparticles was shown in fig. 2. Each is generally characterized by slow release rate, no bust effect was observed. The possible explanation for the slow release rate in the pH 7.4 phosphate buffer USP could be due to deposition of hydrophobic coat over insulin-zinc-HP-β-CD. Degradation of insulin observed over the extended time intervals indicating the instability of human insulin to the experimental conditions.

Bottom Line: Insulin encapsulation efficiency was 95.7±1.2%.Insulin hydrophobic nanoparticles suppressed insulin release promoted sustained release in pH 7.4 phosphate buffer and shown to protect insulin from enzymatic degradation in vitro in presence of chymotripsin.Nanoencapsulated insulin was bioactive, demonstrated through both in vivo and in vitro.

View Article: PubMed Central - PubMed

Affiliation: USV Limited, B. S. D. Marg, Govandi, Mumbai-400 088, India.

ABSTRACT
Insulin loaded hydrophobic nanoparticles were prepared by solvent diffusion followed by lyophilization. Nanoparticles were characterized for mean size by dynamic laser scattering and for shape by scanning electron microscopy. Insulin encapsulation efficiency, in vitro stability of nanoparticles in presence of proteolytic enzymes and in vitro release were determined by high pressure liquid chromatography analysis. The biological activity insulin from the nanopraticles was estimated by enzyme-linked immunosorbant assay and in vivo using Wister diabetic rats. Nanoparticles ranged 0.526±0.071 μm in diameter. Insulin encapsulation efficiency was 95.7±1.2%. Insulin hydrophobic nanoparticles suppressed insulin release promoted sustained release in pH 7.4 phosphate buffer and shown to protect insulin from enzymatic degradation in vitro in presence of chymotripsin. Nanoencapsulated insulin was bioactive, demonstrated through both in vivo and in vitro.

No MeSH data available.